Announcements Trials
Browse Landscape

Phase

Phase 2 2Phase 1/2 1

Status

Completed 2Terminated 1

Sponsor Class

OTHER 20NIH 3NETWORK 1INDUSTRY 1

Study Type

Interventional 3

Sponsor

Cancer Type

Other hematologic neoplasm 3Lymphoid 3

Conditions

Melanoma 7Sarcoma 6Gliosarcoma 6Glioblastoma 6Multiple Myeloma 5Hematologic Neoplasms 5Endometrial Neoplasms 5Carcinoma, Renal Cell 5Brain Neoplasms 5Rhabdomyosarcoma 4Precursor Cell Lymphoblastic Leukemia-Lymphoma 4Lymphoma, Non-Hodgkin 4Hodgkin Disease 4Waldenstrom Macroglobulinemia 3Neoplasms 3Lymphoma, Mantle-Cell 3Lymphoma, Follicular 3Lymphoma, B-Cell, Marginal Zone 3Leukemia, Myeloid, Acute 3Leukemia, Lymphocytic, Chronic, B-Cell 3Unspecified Childhood Solid Tumor, Protocol Specific 2Unspecified Adult Solid Tumor, Protocol Specific 2Tongue Neoplasms 2Squamous Cell Carcinoma of Head and Neck 2Prostatic Neoplasms 2Ovarian Neoplasms 2Osteosarcoma 2Oligodendroglioma 2Lymphoma, T-Cell 2Lymphoma, Large B-Cell, Diffuse 2

Interventions

Rituximab 32fludarabine phosphate 28Cyclophosphamide 26Filgrastim 13Peripheral Blood Stem Cell Transplantation 12ibrutinib 11Bortezomib 11Lenalidomide 10alvocidib 9Cyclosporine 9tanespimycin 8Biopsy 8fludarabine 7Vincristine 7Radiotherapy 7Etoposide 7Specimen Handling 6romidepsin 5bryostatin 1 5apolizumab 5Vorinostat 5Methotrexate 5Ifosfamide 5Cytarabine 5CT-P10 5Busulfan 5temsirolimus 4laromustine 4aldesleukin 4Thalidomide 4

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

3 trials
RecentStart dateEnrollment
NIH × Leukemia, Lymphocytic, Chronic, B-Cell × Sirolimus × Clear all
NCT01381692 2021-10-04

Bortezomib, Rituximab, and Dexamethasone With or Without Temsirolimus in Treating Patients With Untreated or Relapsed Waldenstrom Macroglobulinemia or Relapsed or Refractory Mantle Cell or Follicular Lymphoma

National Cancer Institute (NCI)

Phase 1/2 Completed
9 enrolled 8 charts
LymphoidOther hematologic neoplasm

Lymphoma, Follicular, Lymphoma, Non-Hodgkin, Waldenstrom Macroglobulinemia, Leukemia, Lymphocytic, Chronic, B-Cell, Lymphoma, B-Cell, Marginal Zone, Lymphoma, Mantle-Cell

NCT00290472 2014-05-23

CCI-779 in Treating Patients With Recurrent or Refractory B-Cell Non-Hodgkin's Lymphoma or Chronic Lymphocytic Leukemia

National Cancer Institute (NCI)

Phase 2 Completed
89 enrolled 9 charts
LymphoidOther hematologic neoplasm

Burkitt Lymphoma, Lymphoma, Follicular, Lymphoma, Non-Hodgkin, Waldenstrom Macroglobulinemia, Neoplasms, Leukemia, Lymphocytic, Chronic, B-Cell, Lymphoma, Large-Cell, Immunoblastic, Lymphoma, Large B-Cell, Diffuse, Lymphoma, B-Cell, Marginal Zone, Precursor Cell Lymphoblastic Leukemia-Lymphoma

NCT00086840 2013-01-24

CCI-779 in Treating Patients With Relapsed or Refractory Chronic Lymphocytic Leukemia

National Cancer Institute (NCI)

Phase 2 Terminated
60 enrolled
LymphoidOther hematologic neoplasm

Hodgkin Disease, Leukemia, Lymphocytic, Chronic, B-Cell, Lymphoma, Large B-Cell, Diffuse

Data powered by HemOnc (CC BY 4.0) Colophon âš¡